Lineage Cell Therapeutics, Inc. (LCTX) Fair Value 2026

LCTX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.9 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-28, Lineage Cell Therapeutics, Inc. (LCTX) trades at $1.11. QOC: 6.9/10. Value Trap Risk: 26/100 (LOW). 1/13 models active.

Key Facts

Ticker
LCTX
Price
$1.11
Quality Score
6.9/10
Value Trap Risk
26/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give LCTX?

1 Intrinsic Value Models vs. Current Price ($1.11)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.19 -82.8%

All Models Active

All 1 models are displayed above.

What Is Lineage Cell Therapeutics, Inc. (LCTX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Lineage Cell Therapeutics, Inc.'s intrinsic value is estimated at $0.19, suggesting the stock is overvalued at its current price of $1.11. With 1 out of 1 models flagging downside (-82.8% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About LCTX?

1 of 13 models are currently active for LCTX. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does LCTX Rank in Biotechnology?

Among 625 Biotechnology stocks, LCTX ranks #55 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Lineage Cell Therapeutics, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating LCTX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is LCTX a Value Trap?

CirclFi's Value Trap algorithm assigns LCTX a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Lineage Cell Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Lineage Cell Therapeutics, Inc.'s fundamental quality profile registers 6.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LCTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LCTX's 1 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Lineage Cell Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

FHTXFoghorn Therapeutics Inc.QOC 6.9PLXProtalix BioTherapeutics, Inc.QOC 6.9NRIXNurix Therapeutics, Inc.QOC 6.9FDMT4D Molecular Therapeutics, Inc.QOC 6.8IDYAIDEAYA Biosciences, Inc.QOC 6.9ICCCImmuCell CorporationQOC 6.8ADXNAddex Therapeutics LtdQOC 5.5INTSIntensity Therapeutics, Inc.QOC 4.8MTVAMetaVia Inc.QOC 4.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: FHTX · PLX · NRIX · FDMT · IDYA · ICCC · ADXN · INTS · MTVA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to LCTX?

6 companies across all industries closest to LCTX’s Quality of Company score of 6.9/10.

MSBBMercer Bancorp, Inc.QOC 6.9MNROMonro, Inc.QOC 6.9GSATGlobalstar, Inc.QOC 6.9LSFLaird Superfood, Inc.QOC 6.9GROWU.S. Global Investors, Inc.QOC 6.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MSBB · MNRO · GSAT · LSF · GROW · NVDA

Where Does LCTX Sit in CirclFi's Biotechnology Rankings?

LCTX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Lineage Cell Therapeutics, Inc.’s Valuation?

What is Lineage Cell Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Lineage Cell Therapeutics, Inc. (LCTX). The Quality of Company score is 6.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LCTX overvalued or undervalued right now?

At $1.11, 0 of 1 active models suggest LCTX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Lineage Cell Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.9 mean for LCTX?

Lineage Cell Therapeutics, Inc.'s QOC of 6.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on LCTX?

CirclFi analyzes LCTX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is LCTX a value trap in 2026?

Lineage Cell Therapeutics, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Lineage Cell Therapeutics, Inc. (LCTX) a Quality of Company score of 6.9/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/LCTX/ · Methodology
Primary sources for this LCTX valuation
  • Financial statements: Lineage Cell Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000876343) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LCTX as of ; valuations recomputed .